Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

NCT04909515 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study terminated due to business priorities

Conditions

Neuroblastoma

Interventions

DRUG: Naxitamab
DRUG: GM-CSF
DRUG: Isotretinoin

Sponsor

Y-mAbs Therapeutics